Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain

Journal of Pain Research

Volumn 4, Issue , 2011, Pages 385-392

  Peppin, John F ^a   Majors, Kristine ^b   Webster, Lynn R ^c   Simpson, David M ^d   Tobias, Jeffrey K ^e   Vanhove, Geertrui F ^e  

^a The Pain Treatment Center of the Bluegrass   (United States)

^b Integrated Clinical Trial Services Inc   (United States)

^c Lifetree Clinical Research and Pain Clinic   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e NeurogesX Inc   (United States)

Author keywords

Capsaicin 8 patch; Neuropathic pain; NGX 4010; Patch application related pain

Indexed keywords

EID: 84880951318     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S22954     Document Type: Article

References (26)

1. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol. 2005;4(9):543-555.
2. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18(6):350-354.
3. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009;122(10 Suppl):S22-S32.
4. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 1999;353(9168):1959-1964.
5. Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci. 2001;24:487-517.
6. Cortright DN, Szallasi A. Biochemical pharmacology of the vanilloid receptor TRPV1. An update. Eur J Biochem. 2004;271(10): 1814-1819.
7. Facer P, Casula MA, Smith GD, et al. Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. BMC Neurol. 2007;7:11.
8. Ma W, Zhang Y, Bantel C, Eisenach JC. Medium and large injured dorsal root ganglion cells increase TRPV-1, accompanied by increased alpha2C-adrenoceptor co-expression and functional inhibition by clonidine. Pain. 2005;113(3):386-394.
9. Bley KR. TRPV1 agonist approaches for pain management. In: Gomtsyan A, Faltynek CR, editors. Vanilloid Receptor TRPV1 in Drug Discovery. Hoboken, NJ: John Wiley & Sons, Inc; 2010:325-347.
10. Kennedy WR, Vanhove GF, Lu SP, et al. A randomized, controlled, openlabel study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain. 2010;11(6):579-587.
11. Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev. 1999;51(2):159-212.
12. Backonja MM, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: A randomised, double-blind study. Lancet Neurol. 2008; 7(12):1106-1112.
13. Backonja MM, Malan TP, Vanhove GF, Tobias JK. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an openlabel extension. Pain Med. 2010;11(4):600-608.
14. Irving GA, Backonja MM, Dunteman E, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med. 2011;12(1):99-109.
15. Simpson DM, Brown S, Tobias J. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70(24):2305-2313.
16. Webster LR, Malan TP, Tuchman MM, Mollen MD, Tobias JK, Vanhove GF. A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. J Pain. 2010;11(10):972-982.
17. Simpson DM, Gazda S, Brown S, et al. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage. 2010;39(6):1053-1064.
18. Babbar S, Marier JF, Mouksassi MS, et al. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Ther Drug Monit. 2009;31(4):502-510.
19. Gustoff B. First experience with QUTENZA: Case reports. International Association for the Study of Pain 13th World Congress on Pain, 2010, Montreal, QC. Discussion.
20. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149-158.
21. Webster LR, Tark M, Rauck R, Tobias JK, Vanhove GF. Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia. BMC Neurol. 2010;10:92.
22. Wallace M, Pappagallo M. Qutenza®: A capsaicin 8% patch for the management of postherpetic neuralgia. Expert Rev Neurother. 2011; 11(1):15-27.
23. Eccleston C. Role of psychology in pain management. Br J Anaesth. 2001;87(1):144-152.
24. Johnson MH. How does distraction work in the management of pain? Curr Pain Headache Rep. 2005;9(2):90-95.
25. Linton SJ, McCracken LM, Vlaeyen JW. Reassurance: help or hinder in the treatment of pain. Pain. 2008;134(1-2):5-8.
26. Backonja MM, Walk D, Edwards RR, et al. Quantitative sensory testing in measurement of neuropathic pain phenomena and other sensory abnormalities. Clin J Pain. 2009;25(7):641-647.